Brafi - OmicsDI

Show results for

Unknown (235)
Genomics (94)
Transcriptomics (63)
Proteomics (17)
Clinical (1)
Other (1)

Organisms

Homo sapiens (67)
Andropogon gerardi (14)
Bacteria (14)
Bartonella quintana JK 31 (14)
Canis lupus familiaris (14)
Cnidaria (14)
Ensifer adhaerens (14)
Halictus scabiosae (14)
Human alphaherpesvirus 1 strain 17 (14)
Human alphaherpesvirus 1 strain KOS (14)
Human betaherpesvirus 5 (14)
Human herpesvirus 2 strain 186 (14)
Mesocricetus auratus (14)
Miscanthus x giganteus (14)
Mus musculus (14)
Panicum virgatum (14)
Platyhelminthes (14)
Pseudomonas aeruginosa PA103 (14)
Rabies virus Nishigahara RCEH (14)
Rattus norvegicus (14)
Rattus rattus (14)
Rhodococcus jostii RHA1 (14)
Rhodopseudomonas palustris (14)
Shigella (14)
Sorghastrum nutans (14)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (14)
Streptococcus pneumoniae (14)
Streptomyces coelicolor A3(2) (14)
Mus musculus (10)
synthetic construct (1)

Organisms

Homo sapiens (60)
Mus musculus (9)

Repository

ENA (85)
geo (64)
pride (14)
biostudies-arrayexpress (9)
iProX (3)

Tissue

Cell culture (7)
Melanocyte (5)
Skin (4)
Endothelial cell (2)
Colon (1)
Epithelial cell (1)
Keratinocyte (1)
Permanent cell line cell (1)

Disease

Melanoma (7)
Colon cancer (2)
Colorectal Neoplasms (1)
Melanoma and neural system tumor syndrome (1)

Technology Type

Mass Spectrometry (14)
Shotgun proteomics (7)
Bottom-up proteomics (4)
Data-dependent acquisition (4)
Affinity purification coupled with mass spectrometry proteomics (3)
Top-down proteomics (2)
Gel-based experiment (1)

Instrument Platform

NextSeq 500 (3)
Illumina HiSeq 1500 (1)
Illumina HiSeq 2500 (1)

Publication Date

2025 (19)
2024 (13)
2023 (11)
2017 (11)
2022 (7)
2021 (5)
2020 (4)
2015 (4)
2014 (4)
2026 (4)
2019 (3)
2016 (3)
2018 (2)

First Public Date

2025 (17)
2022 (12)
2023 (11)
2017 (11)
2020 (8)
2026 (6)
2024 (6)
2019 (4)
2021 (3)
2015 (3)
2014 (2)
2018 (1)
2013 (1)

Study status

Recruiting (1)

Study type

Transcription profiling by array (4)
RNA-seq of coding RNA (2)
Cell line - High-throughput sequencing (1)
DNA-seq (1)
RNA-seq of non coding RNA (1)
Interventional (1)

Release Date

2021 (32)
2020 (30)
2022 (27)
2019 (25)
2023 (21)
2025 (19)
2016 (17)
2017 (16)
2024 (15)
2015 (13)
2014 (13)
2018 (13)
2026 (3)

Lab affiliation

Department of Dermatology, Medical University of Vienna (2)
Molecular Oncology Chemical Biology and Molecular Medicine Moffitt Cancer Center & Research Institute, SRB3 12902 Magnolia Drive, Tampa, FL, 33612, USA. (2)
1 Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands. 2 Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands 3 Mass Spectrometry and Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands (1)
Biomolecular Mass Spectrometry and Proteomics Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences Utrecht University (1)
Chair, Quantitative Proteomics Director, Proteome Center Tuebingen Interfaculty Institute for Cell Biology University of Tuebingen Auf der Morgenstelle 15 72076 Tuebingen Germany (1)
Department of Cancer Biology, Dana-Farber Cancer Institute Department of CellBiology, Harvard Medical School (1)
Functional Proteomic Lab, Department of Life Sciences, University of Siena, Siena, Italy (1)
Head of the Curie Institute Mass Spectrometry Platform (1)
Laboratory of Genomic Screening, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy (1)
The First Affiliated Hospital of Jinan University (1)
University of Siena (1)
University of Vienna, Faculty of Chemistry, Department of Analytical Chemistry (1)

Location

China (1)

Keyword

Vemurafenib (1)
Cetuximab (1)

Previous page
1 / 42
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 42
Next page

Sort by:

Relevance

Page size

Untreated A375 cells vs BRAFi/MEKi-treated A375 cells

Quantitative proteomic analysis in untreated A375 cells and BRAFi/MEKi-treated A375 cells

ORGANISM(S): Homo sapiens (Human)

2026-06-18 | PXD068007 | Pride

CNV patterns in BRAFi resistant melanoma cell lines

PRJNA471527 | ENA

Proteomics of BRAFi-treated endothelial cells

Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribu...

ORGANISM(S): Homo sapiens (Human)

2024-06-01 | PXD052251 | Pride

Human Phosphoproteomics Endothelial cells Brafi Vemurafenib

Phosphoproteomics of BRAFi-treated endothelial cells

ORGANISM(S): Homo sapiens (Human)

2024-06-01 | PXD052259 | Pride

Human Phosphoproteomics Endothelial cells Brafi Vemurafenib

Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_1]

PRJNA819952 | ENA

Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_2]

PRJNA973594 | ENA

Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [ChIP-Seq]